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sure of human primary leukocytes to  Acinetobacter sup-
pressed the cytokine response to  Candida albicans  and  S. au-
reus, while the normal corynebacteria did not suppress cyto-
kine responses.  Discussion: These results demonstrate that 
central mediators of immune responses like STAT1 and 
STAT3 not only directly influence immune responses, but 
also result in changes in the skin microbiome that in turn can 
amplify the defective immune response against fungal and 
microbial pathogens.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Chronic mucocutaneous candidiasis (CMC) and hy-
per-IgE syndrome (HIES) are primary immunodeficien-
cies characterized by defective mucosal host defense mech-
anisms due to impaired Th1 and Th17 responses. However, 
how these immune defects affect regular colonizers on the 
skin and mucosa of these patients remains to be deter-
mined. In this study, we investigated the interaction be-
tween the host genotype, microbiome and host immunity.
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 Abstract 
 Background: Chronic mucocutaneous candidiasis (CMC) 
and hyper-IgE syndrome (HIES) are primary immunodefi-
ciencies mainly caused by mutations in STAT1 and STAT3, re-
spectively. CMC and HIES patients have an increased risk for 
skin and mucosal infections with fungal pathogens and 
 Staphylococcus aureus . However, it is unknown whether the 
genetic defects in these patients also affect the skin and mu-
cosal microbiome, which in turn may influence host defense 
mechanisms.  Methods: The skin and oral microbiome of 
CMC and HIES patients was compared to that of healthy con-
trols at five body sites using 16S rRNA sequencing. The influ-
ence of skin colonizers on the immune response was inves-
tigated using in vitro  experiments.  Results: The microbiome 
of CMC and HIES patients contained more Gram-negative 
bacteria, especially  Acinetobacter  spp. , and less of the normal 
 Corynebacterium  spp.  compared to healthy controls. Expo-
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 CMC patients display chronic fungal infections of the 
skin, nails and oropharynx  [1, 2] . CMC is classified into 
autosomal recessive CMC, autosomal dominant CMC, 
and autosomal recessive autoimmune polyendocrinopa-
thy candidiasis ectodermal dystrophy. It has been dem-
onstrated that the latter is caused by mutations in the  au-
toimmune regulator (AIRE)  gene  [3, 4] , leading to the pro-
duction of autoantibodies against IL-17 and IL-22  [5, 6] . 
Recently, we and others have demonstrated that autoso-
mal dominant CMC is mainly caused by dominant nega-
tive mutations in the  signal transduced and activator of 
transcription (STAT) 1  gene  [7–10] . These mutations lead 
to decreased Th1 and Th17 responses, explaining the in-
creased susceptibility to fungal infections and lung pa-
thology seen in these patients  [2, 11, 12] .
 HIES was first described in 1966 as Job’s syndrome  [4, 
13, 14] . HIES is a heterogeneous disease, but the main 
characteristics include increased serum IgE levels, ecze-
matoid dermatitis, recurrent skin and pulmonary infec-
tions with predominantly  Staphylococcus aureus , and 
mucocutaneous candidiasis. Interestingly, autosomal 
dominant HIES is mainly caused by dominant negative 
mutations in the  STAT3  gene  [6, 15–17] . Similar to auto-
somal dominant CMC, these mutations decrease produc-
tion of Th1 and Th17 cytokines  [8–10, 18–22] , explaining 
the increased susceptibility to infections with  Staphylo-
coccus and  Candida species.
 Since HIES and CMC are well-defined primary immu-
nodeficiencies with similar immune defects in mucosal 
and skin immunity, one may hypothesize that the muta-
tions in  STAT1 and  STAT3 could also influence the mi-
croorganisms that colonize the skin and oral mucosa, the 
main sites affected by these diseases. Segata et al.  [23] and 
Kong et al.  [24]  previously demonstrated that patients 
with atopic dermatitis lesions carry a statistically signifi-
cant higher portion of  S. aureus  compared to healthy con-
trols, which may have contributed to the pathogenesis of 
the disease. Since colonizing microorganisms are known 
to modulate the host immune response, we consequently 
hypothesize that a potentially skewed microbiome on the 
skin or mucosa of CMC and HIES patients may further 
increase the imbalance in the host immune response, aug-
menting the immune defects.
 From recent human microbiome studies, the microbial 
communities on the skin are now more comprehensively 
characterized than before, particularly for healthy people 
 [25–27] . In summary, the human skin can be divided into 
three different habitat types: dry, moist and sebaceous ar-
eas; the dry skin areas are the most diverse and contain 
various mixtures of predominantly Actinobacteria, Pro-
teobacteria, Firmicutes and Bacteroidetes.  Staphylococcus 
and  Corynebacterium are the most common organisms on 
moist skin, and the  Propionibacterium is the most abun-
dant phylum present on sebaceous skin areas  [28, 29, 45] .
 No information currently exists on how the host geno-
type specifically affects the skin microbiome in humans, 
whereas several strong interactions have now been de-
scribed between the host genotype and the gut microbi-
ome  [30] . For example, mice with different genetic back-
grounds display quantitative differences in their gut mi-
crobiome  [31, 32] . Khachatryan et al.  [33] demonstrated 
that mutations in the  MEFV gene, leading to familial 
Mediterranean fever, are associated with a decreased 
number and diversity of bacteria in the gut. Furthermore, 
during disease flares, there is a shift in the bacterial popu-
lations within the Bacteroidetes, Firmicutes and Proteo-
bacteria. Li et al.  [1] demonstrated that in patients with 
inflammatory bowel disease there is a correlation be-
tween NOD2 genotype and overall microbial composi-
tion of the ileum. TLR5–/– mice develop hallmark fea-
tures of the metabolic syndrome, and this is correlated to 
an altered gut microbiome. Interestingly, the altered mi-
crobiome in its turn can induce features of the metabolic 
syndrome  [3] .
 Clearly, genetic variation in the host genome can strong-
ly influence the gut microbiome. Unfortunately, informa-
tion on the interaction between the skin microbiome and 
the host immune system is scarce. To our knowledge, the 
only paper published on this subject was about research 
conducted in mice. In 2012, Naik et al.  [5] demonstrated 
that unlike the gut microbiome, the skin microbiome has a 
great influence on immunity against cutaneous pathogens.
 In the current study, the skin and oral microbiome of 
patients with CMC and HIES was compared to that of 
healthy controls. We demonstrate that the microbiome of 
CMC and HIES patients contains more Gram-negative 
bacteria and less of the normal  Corynebacterium  spp. 
compared to that of healthy controls, and that this shift 
has the capacity to impair the host defense against  Can-
dida and staphylococci.
 Materials and Methods 
 Patients and Healthy Controls 
 In January 2012, 4 CMC patients, 7 HIES patients, and 10 age-
matched healthy controls were included in this study. Both HIES and 
CMC are very rare primary immunodeficiencies, with only a few 
hundred patients known worldwide. The hands, feet, trunk, mouth, 
and (if present) the skin lesion were treated aseptically using Catch-
All TM sample collection swabs, moistened with sterile SCF-1 solu-
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tion (50 m M Tris buffer, pH 8, 1 m M EDTA, and 0.5% Tween-20). 
Immediately after the treatment, each swab was swirled in a 2-ml 
collection tube containing 300 μl MicroBead solution. The samples 
were stored at –20  °  C until further processing. Nine healthy controls, 
4 CMC and 2 HIES patients also donated blood for in vitro  immu-
nological studies. The study was approved by the Ethical Committee 
of the Radboud University Nijmegen, and the participants gave writ-
ten informed consent. The study was performed in accordance with 
the Declaration of Helsinki. The patients were asked to stop the use 
of any prophylactic antibiotics 1 week before the initiation of the 
study. Of the 7 patients using antibiotics, 3 used flucloxacillin for the 
prophylaxis of skin staphylococcal infections, and the other patients 
used prophylaxis with different antibiotics for respiratory infections. 
In 1 CMC patient, we were not able to stop antibiotic therapy (co-
trimoxazole/ganciclovir) due to a chronic pulmonary infection and 
CMV infection associated with low CD4 counts.
 Microbial DNA Isolation 
 Microbial DNA was isolated using the UltraClean TM microbial 
DNA isolation kit (MO BIO Laboratories, Uden, The Nether-
lands), according to the manufacturer’s instructions. The presence 
of microbial DNA was confirmed using PCR to detect 16S rRNA 
gene. The following PAGE-purified primers were used: F338: 
5 ′ -act-cct-acg-gga-ggc-agc-ag-3 ′ (V3) and 1061R: 5 ′ -crr-cac-gag-
ctg-acg-ac-3 ′ (V6; Biolegio, Nijmegen, The Netherlands). PCR was 
performed using KOD DNA polymerase (EMD Millipore, Am-
sterdam, The Netherlands) as follows: 2 min at 95  °  C, followed by 
30 cycles of 20 s at 95   °   C; 10 s at 55   °   C; 15 s at 70   °   C followed by 
10 min at 70  °  C; 5 μl of PCR product was checked on agarose gel.
 16S rRNA Gene Profiling and Sequencing 
 The 16S rRNA gene dataset consists of Illumina MiSeq paired-
end sequences targeting the V4 variable region. Genomic DNA 
was subjected to 16S amplifications using the 515 forward and 806 
reverse primers, as previously described in detail  [7] , with the fol-
lowing modifications: (1) only one PCR amplification was per-
formed instead of three; (2) only 30 PCR cycles instead of 35; (3) 
an extension time of 5 instead of 1.5 min to reduce chimera forma-
tion; (4) size selection was applied to retrieve amplicons between 
375 and 425 bp using Sage Pippin Prep, in order to reduce aspe-
cific amplification products derived from host DNA, and (5) the 
amplicons were sequenced for 175 bases in each direction, using 
custom-designed primers that are complimentary to the V4 am-
plification primers. Sequencing was performed according to the 
manufacturer’s specifications.
 Processing 16S rRNA Gene Sequence Data 
 Sequences were processed using a pipeline implemented in 
QIIME 1.4.0  [11] as pick_reference_otus_through_otu_table.py, 
which picks OTUs by mapping the sequences against a subset of 
the latest Greengenes database (version October 2012)  [13] fil-
tered at 97% identity, resulting in a table of counts by OTU and 
sample, with a representative sequence for each OTU. Classifica-
tion was used as provided through Greengenes. The resulting 
OTU tables were checked for mislabeling  [15] and contamination 
 [18] , and further microbial community analysis and visualiza-
tions. Statistical association analysis was done both with a uni-
variate approach using LEfSe  [23, 34] and a multivariate approach, 
as described previously  [25, 27] . LEfSe is a nonparametric facto-
rial Kruskal-Wallis rank-sum test to detect organisms with sig-
nificant differential abundance between sample sets; biological 
significance is subsequently investigated using a set of pairwise 
tests among subclasses using the (unpaired) Wilcoxon rank-sum 
test. As a last step, LEfSe uses linear discriminant analysis to esti-
mate the effect size of each differentially abundant feature.
 Isolation of PBMC 
 PBMC were obtained by density centrifugation of diluted 
blood (1 part blood to 1 part pyrogen-free saline) over Ficoll-Paque 
(Pharmacia Biotech, Uppsala, Sweden). PBMC were washed twice 
in saline and suspended in culture medium (RPMI 1640 Dutch 
modifications; Sigma-Aldrich, Zwijndrecht, The Netherlands) 
supplemented with 1% gentamicin, 1%  L -glutamine and 1% pyru-
vate (Life Technologies, Nieuwekerk, The Netherlands). The cells 
were counted in a hemocytometer, and their number was adjusted 
to 5 × 10 6 cells/ml.
 Microorganisms 
 Candida albicans American Type Culture Collection (ATCC) 
MYA-3573 (UC 820) was grown overnight in Sabouraud broth 
at 37  °  C, and cells were harvested by centrifugation, washed twice, 
and resuspended in culture medium.  C. albicans was heat killed for 
1 h at 100  °  C.  S. aureus  25923 was heat killed for 30 min at 100  °  C. 
 Acinetobacter baumannii (ATCC-15308) and  Corynebacterium 
 jeikeium (ATCC-BAA-949) were obtained from ATCC, grown 
overnight, harvested by centrifugation, washed twice, and resus-
pended in culture medium.
 In vitro Stimulation Assays 
 5 × 10 5 PBMC in a volume of 100 μl/well were prestimulated 
for 24 h at 37   °   C in round-bottom 96-well plates (Greiner, Nurn-
berg, Germany) with  C. jeikeium,  A. baumannii or  S. aureus  (1 × 
10 6 /ml). Cells were restimulated with  C. albicans  (1 × 10 6 /ml)  or 
 S. aureus (1 × 10 7 /ml) for 24 h or 7 days. When cells were stimu-
lated for 7 days, this was done in the presence of 10% human 
pooled serum. Experiments were performed in duplicate. After 1 
or 7 days of incubation, duplicate supernatants were pooled and 
stored at –20  °  C until assayed.
 Cytokine Assays 
 The concentrations of IL-1β, IL-17, IL-22 and TNF-α (R&D Sys-
tems, Abingdon, UK) and IFNγ (Sanquin, Amsterdam, The Neth-
erlands) were measured in cell culture supernatants using ELISA 
according to the manufacturers’ instructions. These particular cy-
tokines were measured because they play an important role in the 
host immune response against  C. albicans  [35] and  S. aureus  [36] .
 Immunological Statistical Analysis 
 The differences between groups were analyzed using the Wil-
coxon signed-rank test. All statistical analyses were 2-sided, and 
differences were considered statistically significant if p  ≤ 0.05 ( * ) 
or p  ≤ 0.01 ( * * ).
 Results 
 Patient and Control Characteristics 
 The microbiome structure of 11 immunodeficient pa-
tients (4 CMC and 7 HIES patients) was obtained from 
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several skin and oral locations during their regular visit in 
the outpatient clinic (January 2012). In addition, 10 non-
affected healthy individuals served as controls. Controls 
were matched for age but not gender, as it was previously 
shown that this is not associated with substantial varia-
tion in the human micriobiome  [2, 27] . At the time of 
sampling, 4 of 4 CMC and 1 of 7 HIES patients had an 
active skin lesion, which was also sampled ( table 1 ). DNA 
was extracted from skin and oral samples, and the 16S 
rRNA gene was amplified and sequenced on the Illumina 
MiSeq platform. The resulting sequences were then pro-
cessed with QIIME taking a reference-based approach. At 
the end of this process, the median sequencing depth was 
6,389 reads per sample.
 Sample Diversity 
 We compared the microbial community profiles 
among subjects to relate disease phenotype to variation 
in microbiome structure ( fig. 1 ). Oral and skin samples 
were analyzed separately, as between-site variation in 
the human microbiome is greater than between-subject 
within-site variation  [4, 27] . The skin microbiome com-
position was very similar among healthy controls and 
was dominated by  Staphylococcus ,  Streptococcus and 
 Corynebacterium, as expected. In contrast, in HIES and 
CMC patients, there was more variation in microbiome 
structure, which was characterized by an increase in 
Moraxellaceae (mainly  Actinobacter;  fig. 1 a). The oral 
samples of healthy controls are largely defined by the 
presence of  Prevotella  and  Fusobacterium , with an ef-
fect of disease on oral composition in a nonunidirec-
tional way ( fig. 1 b). In general, both CMC and HIES pa-
tients have relatively little Gram-positive bacteria on 
their hands and feet compared to healthy controls 
( fig. 2 ). The relative abundance of phyla per individual 
is displayed in online supplementary figure 1 (for all 
online suppl. material, see www.karger.com/doi/ 
10.1159/000351912).
Table 1.  Baseline characteristics of the participants
Characteristics CMC
patients
HIES
patients
Age-matched
healthy controls
Number 4 7 10
Gender, male:female 2:2 5:2 8:2
Age (mean ± SD), years 46±16 46±5 47±10
Active lesion 4 (100%) 2 (29%) –
Genetic defect STAT1 STAT3 –
Fig. 1. Covariance of skin and oral microbial community structure 
with disease subtype in immunodeficient patients. The variation 
in microbial diversity of 35 skin ( a ) and 21 oral samples ( b ) from 
healthy controls (green squares), and patients with CMC (red cir-
cles) and HIES (blue triangles). The principal coordinate plot uses 
the weighted UniFrac β-diversity metric, with the covariance of 
selected microbial taxa overlaid as a biplot. Organisms character-
istic for the healthy skin samples are  Staphylococcus and  Coryne-
bacterium spp., with  Moraxellaceae spp. driving the different com-
munities in disease.
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 Assessing Significant Covariation of the Microbiome 
Structure with Disease 
 Next, we looked in more detail at the differences be-
tween healthy controls and immunodeficient patients us-
ing univariate association tests, taking into account dis-
ease phenotype and body site for skin samples. The re-
sults found in skin samples were verified using 
multivariate tests ( fig. 3 , online suppl. table 1). Using the 
univariate LEfSe test for microbial biomarkers, we ob-
served lower levels of  Corynebacterium  on the hands and 
feet of HIES patients. On the other hand, the levels of  Aci-
netobacter  were strongly increased in both HIES and 
CMC patients ( fig.  3 a). The relative abundance of  Pre-
votella  and  Fusobacterium , which  are key species in oral 
samples of healthy controls, was lower in both CMC and 
HIES patients ( fig. 3 b). The composition of the microbi-
ome in skin lesions varied substantially between immu-
nocompromised individuals, but in general contained a 
lot of Fusobacteria  and Firmicutes (data not shown). 
There was no significant association between microbi-
ome composition and gender (data not shown).
 CMC-/HIES-Related Skin Colonizers Impair Innate 
Immune Host Responses 
 To investigate whether microorganisms abundantly 
found on the skin of CMC and HIES patients can modi-
fy host immune responses to the pathogens encountered 
in these diseases ,  PBMC of healthy volunteers were ex-
posed either to  C. jeikeium (normal colonizer) , A. bau-
mannii  (HIES/CMC colonizer)  or  S. aureus (CMC colo-
nizer). After 24 h of incubation, the cells were restimu-
lated with  C. albicans  or  S. aureus.  Exposure of PBMC 
to  Corynebacterium normally found in the human skin 
microbiota did not affect  Candida- and  Staphylococcus -
induced cytokine responses. In contrast, exposure of im-
mune cells to  Acinetobacter found on the skin of HIES 
and CMC patients strongly inhibited the normal TNF, 
IFNγ and IL-22 responses of human PBMC, while the 
IL-1β and IL-17 responses remained relatively unaffect-
ed ( fig. 4 ). A similar inhibitory effect on TNF and IFNγ 
production by  Acinetobacter was found in PBMC iso-
lated from CMC and HIES patients (data not shown), 
while PBMC of CMC and HIES patients already had ab-
sent IL-17 and IL-22 production due to their genetic de-
fect  [6, 22, 37] .
 Discussion 
 In this study, we characterized the microbiome of 
CMC and HIES patients and compared it to that of 
healthy controls. The skin and oral microbiota of our 
healthy controls was dominated by typical human-asso-
ciated phyla, mainly the  Firmicutes and Proteobacteria, 
as expected  [8–10, 27] . In contrast, patients with HIES 
displayed significantly decreased colonization by  Coryne-
bacterium, while Acinetobacter  was more prevalent in 
both CMC and HIES patients. Additionally, exposure of 
0
0.5
1.0
1.5
HC CM
C HIES
Hand
HC CM
C HIES
Foot
HC CM
C HIES
Trunk
HC CM
C HIES
Mouth
CM
C HIES
Lesion
G+/G–%
Gram+
Gram–
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1–10 subjects. HC = Healthy controls.  
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healthy PMBC to  Acinetobacter decreased subsequent cy-
tokine production in response to either  C. albicans or 
 S. aureus exposure.
 This is one of the first studies on the microbiome of 
patients with a primary immunodeficiency. Because of 
their specific defects in cellular immunity, the microbiota 
of patients with  STAT1 and  STAT3 mutations provide a 
unique opportunity to define the role of Th17 immunity 
for the composition of the normal flora of an individual. 
One important observation of the present study was the 
identification of an overrepresentation of Gram-negative 
bacteria (particularly  Acinetobacter  spp. ) in the skin mi-
 Fig. 3. Selected associations of microbial clade abundance with 
body site and disease subtype. A subset of taxa that significantly 
differs in relative abundance as determined by LEfSe between dis-
ease subtypes at skin ( a ) or oral body sites ( b ). Subclasses of disease 
subtype are separated, with specific body sites differentially col-
ored. The mean and median relative abundance of the taxa are 
indicated with solid and dashed lines, respectively (LEfSe  *   p < 
0.05). 
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crobiome of patients with  STAT1/STAT3 defects, where-
as the presence of the normal  Corynebacterium was de-
creased. This is interesting in that it mirrors the findings 
of previous work in patients with multifactorial diseases 
like psoriasis  [2, 12, 38] , chronic obstructive pulmonary 
disease  [4, 14, 39] , or atopic dermatitis  [6, 16, 17, 24] . In 
patients with atopic dermatitis flares, the amount of  Co-
rynebacterium  is decreased  [8–10, 19–22, 24] similar to 
CMC and HIES patients.
 The functional consequence for the immune system of 
the shift from normal to Gram-negative flora in the CMC 
and HIES patients was investigated by exposing human 
primary leukocytes to either  Corynebacterium or  Aci-
netobacter before their stimulation with  C. albicans or 
 S.  aureus . They are two of the relevant pathogens for 
these diseases, as CMC and HIES patients often suffer 
from skin infections with fungal pathogens (especially 
dermatophytes) and HIES patients from skin abscesses 
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 Fig. 4.  Acinetobacter suppress typical immune responses. PBMC 
of healthy volunteers were prestimulated for 24 h with RPMI,  Co-
rynebacterium, Acinetobacter or  Staphylococcus, and stimulated 
with  C. albicans  or  S. aureus  for 1 or 7 days. Cytokine concentra-
tions were measured in cell culture supernatants using ELISA. 
Bars represent means + SEM of 10 healthy volunteers (Wilcoxon 
 *  p < 0.05,  * *  p < 0.01).
 Smeekens   et al.
 
J Innate Immun 2014;6:253–262
DOI: 10.1159/000351912
260
with  S. aureus  [24, 40] . While  Corynebacterium  did not 
impair antifungal and antistaphylococcal responses, ex-
posure of human PBMC to  Acinetobacter significantly 
inhibited their capacity to produce proinflammatory cy-
tokines such as TNF or IFNγ when stimulated with  C. al-
bicans or  S. aureus . Both cytokines are crucial for host 
defense against these two pathogens. Thus, while CMC 
and HIES patients have IL-17 immune defects mediated 
by mutations in  STAT1 or  STAT3 , the microbiome 
skewed towards a Gram-negative microflora amplifies 
the susceptibility to infection by inhibiting TNF and 
IFNγ responses ( fig. 5 ). Recently, the role of skin micro-
biota for T-cell responses has been demonstrated to in-
volve IL-1-receptor-dependent innate immune signals in 
mice  [5, 26, 27] . Our data confirm and extend for the first 
time these observations to humans, in whom the shifted 
microbiota of patients with immunodeficiencies has the 
capacity to impair normal cellular immune responses.
 Remarkably, the presence of  Staphylococcus  was not 
significantly increased across all HIES patients despite 
Fig. 5.  Acinetobacter suppresses TNF-α, 
IFNγ and IL-22. Proposed model of typical 
interactions between the microbiome and 
the immune system in healthy individuals 
( a ) and STAT1/STAT3 immunodeficient 
patients ( b ).
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its regular role in skin abscesses  [14, 28, 29] . This could 
be related to the prophylaxis with narrow-spectrum an-
tibiotics specifically directed towards  S. aureus , such as 
flucloxacillin  [30, 41] , which have been used previously 
by some of the patients. Although the HIES patients 
stopped the antibiotics before the collection of the mi-
crobiome samples, we cannot exclude that the long-
term use of these regimens may be the cause of the low 
colonization with staphylococci. Previously, it has been 
demonstrated that  S. aureus can secrete chemotaxis-in-
hibitory protein of staphylococci, which binds to the 
formyl peptide receptor and C5a on neutrophils, there-
by interfering with neutrophil chemotaxis  [31, 32, 42] . 
Interestingly, neutrophils are a critical component of in-
nate immunity with respect to  C. albicans  infections. 
Therefore, the excess  S. aureus found in CMC patients 
might be another factor explaining their reduced resis-
tance to  C. albicans  infections. It might be interesting to 
learn whether the skin microbiome of these patients is 
also affected with respect to fungal colonization. How-
ever, better tools to detect fungal species still need to be 
developed  [33, 43] .
 The present study has also a few limitations. Firstly, 
we do not have direct information on the actual bacte-
rial loads, which might play an important role in the 
emergence of infections, as we only measured the rela-
tive abundance of different bacterial 16S genes. Kembel 
et al.  [44] demonstrated that correcting for an estimated 
amount of 16S gene copy number for all species can alter 
the community structure. Because of the above-men-
tioned reasons, the bacterial numbers used in the stimu-
lation experiments might not fully reflect the in vivo  sit-
uation, but they nevertheless enabled us to study the im-
munomodulatory effect of the bacteria identified in the 
CMC/HIES microbiome. Secondly, these data are based 
on a relatively small cohort containing only 4 CMC and 
7 HIES patients. CMC and HIES are both very rare dis-
eases, making it impossible for us to include more pa-
tients at this time. However, all these patients are very 
homogeneous in terms of their immune defects, and the 
clear changes in microbiome suggest that the shifts 
identified are real. Nevertheless, larger studies to vali-
date the data presented here are warranted. Thirdly, 
some of the CMC and HIES patients were treated with 
antibiotics and antifungals in the period preceding the 
study, although with the exception of a CMC patient 
they temporarily stopped them prior to sampling. In ad-
dition, the patients recruited in this study were not hos-
pitalized (with the exception of the same patient being 
continuously treated), precluding the possibility of hos-
pital-acquired microorganisms. Antibiotic use has been 
associated with decreased bacterial diversity, and the 
prior antibiotic regimens used by some of the patients 
directed against fungi and staphylococci may have shift-
ed the microbiome towards a Gram-negative bacterial-
dominated colonization. This does not however influ-
ence the conclusion that CMC and HIES patients are 
colonized with relatively many Gram-negative bacteria, 
and that they can influence normal innate immune re-
sponses.
 In conclusion, the assessment of the skin and oral mi-
crobiome of CMC and HIES patients with  STAT1 / STAT3 
mutations and Th17 defects shows a shift of the micro-
biota from normal microorganisms such as  Corynebacte-
rium  and Actinomycetaceae  to a Gram-negative coloni-
zation with genera such as Acinetobacter . Importantly, 
Gram-negative colonization is capable of inhibiting im-
mune responses to  Candida and  S. aureus , likely contrib-
uting to the increased susceptibility of the patients to 
these infections. These data in patients with immunode-
ficiencies prove that the microbiome can influence 
host defense and could open the possibility of microbi-
ome-based adjuvant therapy in patients with immune de-
fects.
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